Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a global biopharmaceutical company, announced its financial results for the full year ended 31 December 2020 on Wednesday.
The company reported income before taxes at USD31.7m in 2020 compared to USD29m in 2019.
The firm posted net income of USD23.3m in 2020, compared to net income of USD115.6m in 2019. It reported diluted net income per share of USD0.42 in 2020 compared to diluted net income per share of USD2.11 in 2019.
'I am very proud of the significant accomplishments we realised during this challenging year,' said Mihael H Polymeropoulos, Vanda's MD, president and CEO.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation